Lebwohl, M., Strober, B., Scharnitz, T., Linaberry, M., Hoyt, K., Banerjee, S., Kisa, R. M., & Martin, G. (2023). Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials. SKIN The Journal of Cutaneous Medicine, 7(6), s244. https://doi.org/10.25251/skin.7.supp.244